Published in Clin Pharmacol Ther on May 01, 1991
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis (2005) 2.48
Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes. J Pharmacokinet Biopharm (1992) 1.07
Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. Br J Clin Pharmacol (1992) 0.96
Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol (2001) 0.96
Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitus. Ther Drug Monit (2014) 0.86
Assessment of the impact of dosing time on the pharmacokinetics/pharmacodynamics of prednisolone. AAPS J (2008) 0.81
LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed (1983) 4.02
Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm (1993) 3.96
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn (2001) 3.21
Cervical screening and health inequality in England in the 1990s. J Epidemiol Community Health (2003) 2.67
Lymphocyte blast transformation. I. Demonstration of adrenergic receptors in human peripheral lymphocytes. Cell Immunol (1970) 2.58
The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection. N Engl J Med (1981) 2.15
Gentamicin disposition and tissue accumulation on multiple dosing. J Pharmacokinet Biopharm (1977) 1.90
Tissue persistence of gentamicin in man. JAMA (1977) 1.79
Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects. Clin Pharmacol Ther (1973) 1.74
Stimulation of leukocyte adenyl cyclase by hydrocortisone and isoproterenol in asthmatic and nonasthmatic subjects. J Allergy Clin Immunol (1972) 1.71
Prednisone side-effects and serum-protein levels. A collaborative study. Lancet (1971) 1.67
Vancomycin anaphylaxis and successful desensitization. Ann Allergy (1994) 1.64
Contribution of cigarette smoking to cadmium accumulation in man. Lancet (1972) 1.63
Enhanced biotransformation of theophylline in marihuana and tobacco smokers. Clin Pharmacol Ther (1978) 1.59
Effect of smoking on theophylline disposition. Clin Pharmacol Ther (1976) 1.58
Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharm Sci (1979) 1.56
Autonomic imbalance in asthma with special reference to beta adrenergic blockade. Adv Intern Med (1972) 1.56
Accumulation pharmacokinetics of tobramycin. Antimicrob Agents Chemother (1978) 1.51
Effects of change in elimination on varous parameters of the two-compartment open model. J Pharm Sci (1972) 1.51
Gentamicin tissue accumulation and nephrotoxic reactions. JAMA (1978) 1.49
Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther (1977) 1.48
Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol (1998) 1.46
Free radical scavenging and antioxidant activity of plant flavonoids. Adv Exp Med Biol (1994) 1.45
Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J Pharmacokinet Biopharm (1998) 1.43
Effect of food on hepatic blood flow: implications in the "food effect" phenomenon. Clin Pharmacol Ther (1983) 1.43
Antiviral effect of flavonoids on human viruses. J Med Virol (1985) 1.43
Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther (2008) 1.42
The anatomical and biochemical basis of bronchial obstruction in asthma. Ann Intern Med (1965) 1.42
Theophylline disposition in obesity. Clin Pharmacol Ther (1978) 1.42
Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm (1996) 1.38
Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther (2001) 1.38
Comparison of ampicillin and hetacillin pharmacokinetics in man. J Pharm Sci (1973) 1.35
Theophylline secretion into breast milk. Pediatrics (1976) 1.35
Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci (1998) 1.34
Theophylline pharmacokinetics in premature infants with apnea. J Pediatr (1976) 1.34
Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin Pharmacol Ther (1989) 1.32
Antiasthmatic drug therapy and calcium ions: review of pathogenesis and role of calcium. J Pharm Sci (1980) 1.28
Cadmium accumulation im man: influence of smoking, occupation, alcoholic habit and disease. J Chronic Dis (1972) 1.27
Pharmacokinetic/Pharmacodynamic models for corticosteroid receptor down-regulation and glutamine synthetase induction in rat skeletal muscle by a Receptor/Gene-mediated mechanism. J Pharmacol Exp Ther (1999) 1.27
Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob Agents Chemother (2006) 1.26
Metabolic response to epinephrine in bronchial asthma. J Allergy (1968) 1.26
Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci (1998) 1.26
Allergy-related diseases and cancer: an inverse association. Am J Epidemiol (1985) 1.25
Influence of cigarette smoking on drug metabolism in man. Drug Metab Rev (1979) 1.23
Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab Rev (1976) 1.22
Analysis of methylprednisolone, methylprednisone and corticosterone for assessment of methylprednisolone disposition in the rat. J Chromatogr (1988) 1.22
Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods. J Pharmacokinet Biopharm (1999) 1.22
Urinary casts as an indicator of renal tubular damage in patients receiving aminoglycosides. Antimicrob Agents Chemother (1979) 1.21
Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J Pharm Sci (1971) 1.19
Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci (1984) 1.18
Comparison of chromatographic and spectrophotometric analysis of indocyanine green in plasma following administration of multiple doses to humans. J Pharm Sci (1982) 1.18
Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci (1993) 1.17
Dose-dependence and repeated-dose studies for receptor/gene-mediated pharmacodynamics of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J Pharmacokinet Biopharm (1998) 1.17
Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm (1999) 1.17
Role of tobacco smoking in pharmacokinetics. J Pharmacokinet Biopharm (1978) 1.16
IgE levels in sera of children with asthma. Pediatrics (1971) 1.15
Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships. Biochem Pharmacol (1989) 1.15
Pharmacokinetics of aztreonam in patients with gram-negative infections. Antimicrob Agents Chemother (1985) 1.15
Cost effectiveness of the Expert Patients Programme (EPP) for patients with chronic conditions. J Epidemiol Community Health (2008) 1.15
A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am Rev Respir Dis (1989) 1.14
Digoxin pharmacokinetics: role of renal failure in dosage regimen design. Clin Pharmacol Ther (1975) 1.11
Pharmacokinetics of methicillin in patients with cystic fibrosis. J Infect Dis (1977) 1.10
Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (1993) 1.10
Ascorbic acid-enhanced antiproliferative effect of flavonoids on squamous cell carcinoma in vitro. Anticancer Drugs (1993) 1.10
Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics (1975) 1.09
Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm (1986) 1.09
Fluorometric analysis of ampicillin in biological fluids. J Pharm Sci (1971) 1.09
Role of parainfluenza virus-specific IgE in pathogenesis of croup and wheezing subsequent to infection. J Pediatr (1982) 1.08
Algorithm for application of Fourier analysis for biorhythmic baselines of pharmacodynamic indirect response models. Chronobiol Int (2000) 1.07
Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes. J Pharmacokinet Biopharm (1992) 1.07
Intravenous theophylline therapy: nomogram guidelines. Ann Intern Med (1977) 1.07
Precipitation of diazepam from intravenous preparations. JAMA (1973) 1.07
Pharmacokinetics of theophylline in hepatic disease. Chest (1978) 1.07
Effect of hydrocortisone on immunoglobulin synthesis and secretion by human peripheral lymphocytes in vitro. Int Arch Allergy Appl Immunol (1972) 1.06
Early detection of aminoglycoside nephrotoxicity with urinary beta-2-microglobulin. J Med (1978) 1.05
Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment. Antimicrob Agents Chemother (1982) 1.05
Corticosteroid analysis in biological fluids by high-performance liquid chromatography. J Chromatogr (1979) 1.04
Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. Clin Pharmacol Ther (1988) 1.04
Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics. J Pharmacokinet Biopharm (1991) 1.03
Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm (1981) 1.03
Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. Br J Pharmacol (1999) 1.03
Quercetin: an inhibitor of antigen-induced human basophil histamine release. J Immunol (1981) 1.03
Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking. J Pharmacokinet Biopharm (1994) 1.02
Role of calcium and calcium antagonists in airway function. Eur J Respir Dis Suppl (1983) 1.02
Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J Clin Pharmacol (1998) 1.01
Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol (1992) 1.00
Active metabolites of imipramine and desipramine in man. Clin Pharmacol Ther (1982) 0.99
Nonlinear assessment of phenytoin bioavailability. J Pharmacokinet Biopharm (1976) 0.99
Pharmacokinetics of cyclophosphamide in man. Br J Pharmacol (1971) 0.99
Role of baseline parameters in determining indirect pharmacodynamic responses. J Pharm Sci (1999) 0.99
Molar quantification of specific messenger ribonucleic acid expression in northern hybridization using cRNA standards. Anal Biochem (1993) 0.98
Pharmacokinetics of methylprednisolone sodium succinate and methylprednisolone in patients undergoing cardiopulmonary bypass. Pharmacotherapy (1990) 0.98
Flavonoid inhibition of human basophil histamine release stimulated by various agents. Biochem Pharmacol (1984) 0.98